1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1689770141

DR. HOWARD MARTIN FILLIT MD
Prescription History 1689770141
Internal Medicine - Geriatric Medicine in New York, NY

NPI Status: Active since September 15, 2006

Contact Information

121 E 60TH ST
NEW YORK, NY
ZIP 10022
Phone: (212) 758-4633

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. HOWARD MARTIN FILLIT MD, an active Geriatric Medicine specialist practicing in New York, NY. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 134 documented patient claims. Among these therapy options, the most frequently utilized medication is Donepezil Hcl, which accounts for 64 claims alone.

Medication Index

D
G
R
No matching medications currently found on file.

Donepezil Hcl

Generic Formulation: Donepezil HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 64
30-Day Fills 93.0
Days Supply 2,790
NY State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills96.8
Peer Average Days Supply2,781
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $814.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.73

State Avg Cost Per Claim

$14.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to function. This medication is an enzyme blocker that works by restoring the balance of natural substances (neurotransmitters) in the brain.

Galantamine Er

Generic Formulation: Galantamine HbrSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 19
30-Day Fills 35.0
Days Supply 1,050
NY State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills78.2
Peer Average Days Supply2,269
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.7% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,301.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$121.11

State Avg Cost Per Claim

$111.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Galantamine is used to treat mild to moderate confusion (dementia) related to Alzheimer's disease. It does not cure Alzheimer's disease, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Riluzole

Generic Formulation: RiluzoleSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 51
30-Day Fills 78.4
Days Supply 2,352
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills52.3
Peer Average Days Supply1,526
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.7% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,657.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$228.58

State Avg Cost Per Claim

$229.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Therapeutic Applications

This medication is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). Riluzole helps to slow down the worsening of this disease and prolong survival.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. HOWARD MARTIN FILLIT MD provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Geriatric Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.